pentamidine has been researched along with Adverse Drug Event in 12 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Both co-trimoxazole and pentamidine are used for the treatment of pneumocystis pneumonia (PCP) and are known to cause hypoglycemia as an adverse drug reaction." | 7.91 | Consecutive hypoglycemia attacks induced by co-trimoxazole followed by pentamidine in a patient with acquired immunodeficiency syndrome. ( Asagiri, T; Nakamura, M; Okazaki, M; Takeuchi, S, 2019) |
| "Both co-trimoxazole and pentamidine are used for the treatment of pneumocystis pneumonia (PCP) and are known to cause hypoglycemia as an adverse drug reaction." | 3.91 | Consecutive hypoglycemia attacks induced by co-trimoxazole followed by pentamidine in a patient with acquired immunodeficiency syndrome. ( Asagiri, T; Nakamura, M; Okazaki, M; Takeuchi, S, 2019) |
| "Pentamidine was initially used as metanolsulfonate or mesylate (Lomidine) at a dose of 4 mg/kg/daily, containing 2." | 2.87 | An open label randomized clinical trial comparing the safety and effectiveness of one, two or three weekly pentamidine isethionate doses (seven milligrams per kilogram) in the treatment of cutaneous leishmaniasis in the Amazon Region. ( Allan Villa Rouco da Silva, G; Chrusciak Talhari Cortez, C; Chrusciak Talhari, A; da Costa Oliveira, B; de Oliveira Guerra, JA; Gabrielle Ramos de Mesquita, T; Gadelha, EPN; Morais Rocha, N; Ramasawmy, R, 2018) |
| "Pafuramidine for the treatment of first stage HAT was comparable in efficacy to pentamidine after 10 days of dosing." | 2.82 | Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies. ( Allen, JL; Bernhard, SC; Bilenge, CM; Blum, J; Burri, C; Josenando, T; Lubaki, JP; Lutumba, P; Manuel, F; Merolle, A; Mesu, VK; Mpanya, A; Mpoto, AM; Munungu, BF; Olson, CA; Pohlig, G; Serge, KK; Thompson, M; Tidwell, RR; Yeramian, PD, 2016) |
| " The primary safety outcome was the frequency and severity of adverse events." | 2.82 | Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial. ( Bernhard, SC; Bilenge, CM; Blum, J; Burri, C; Dala, A; Deo, GK; Dituvanga, ND; Franco, JR; Kuikumbi, FM; Lubaki, JP; Macharia, S; Mesu, VK; Mintwo, AF; Mpanya, A; Mpoto, AM; Munungi, AK; Munungu, BF; Mutantu, PN; N'tombe, PM; Olson, CA; Pohlig, G; Tidwell, RR, 2016) |
| " The objective of this review was to identify and classify the main adverse effects associated with these drugs and to estimate the frequency of these effects, whenever possible." | 2.47 | Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World. ( Andrade, CA; Martins, MM; Marzochi, MC; Oliveira, LF; Oliveira, RV; Passos, SL; Schubach, AO, 2011) |
| "Aerodigestive adverse effects (AD-AE) during intravenous pentamidine (IV-P) infusion for Pneumocystis jiroveci pneumonia prophylaxis are uncommon in retrospective chart review studies." | 1.62 | Aerodigestive adverse effects during intravenous pentamidine infusion for Pneumocystis jirovecii pneumonia prophylaxis. ( George, A; McGraw, BJ; Rademacher, H; Savaşan, S; Sokolowski, C, 2021) |
| "We retrospectively reviewed records of all pediatric HCT patients who received bimonthly IV pentamidine between December 2006 and June 2013, and collected data regarding demographics, clinical course, prophylaxis rationale, laboratory values and adverse events." | 1.43 | Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population. ( Cowan, MJ; Dvorak, CC; Lang, T; Levy, ER; Musick, L; Weintrub, PS; Zinter, MS, 2016) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Koon, A | 1 |
| He, J | 1 |
| Patel, J | 1 |
| Morse, A | 1 |
| Boseman, V | 1 |
| Hamilton, A | 1 |
| Knight, T | 1 |
| Shah, N | 1 |
| Ragon, B | 1 |
| Chojecki, A | 1 |
| Ai, J | 1 |
| Steuerwald, N | 1 |
| Gerber, J | 1 |
| Copelan, E | 1 |
| Grunwald, M | 1 |
| Arnall, J | 1 |
| Savaşan, S | 1 |
| George, A | 1 |
| Sokolowski, C | 1 |
| McGraw, BJ | 1 |
| Rademacher, H | 1 |
| Okazaki, M | 2 |
| Nakamura, M | 1 |
| Asagiri, T | 1 |
| Takeuchi, S | 1 |
| Gadelha, EPN | 1 |
| Ramasawmy, R | 1 |
| da Costa Oliveira, B | 1 |
| Morais Rocha, N | 1 |
| de Oliveira Guerra, JA | 1 |
| Allan Villa Rouco da Silva, G | 1 |
| Gabrielle Ramos de Mesquita, T | 1 |
| Chrusciak Talhari Cortez, C | 1 |
| Chrusciak Talhari, A | 1 |
| Levy, ER | 1 |
| Musick, L | 1 |
| Zinter, MS | 1 |
| Lang, T | 1 |
| Cowan, MJ | 1 |
| Weintrub, PS | 1 |
| Dvorak, CC | 1 |
| Burri, C | 2 |
| Yeramian, PD | 1 |
| Allen, JL | 1 |
| Merolle, A | 1 |
| Serge, KK | 1 |
| Mpanya, A | 2 |
| Lutumba, P | 1 |
| Mesu, VK | 2 |
| Bilenge, CM | 2 |
| Lubaki, JP | 2 |
| Mpoto, AM | 2 |
| Thompson, M | 1 |
| Munungu, BF | 2 |
| Manuel, F | 1 |
| Josenando, T | 1 |
| Bernhard, SC | 2 |
| Olson, CA | 2 |
| Blum, J | 2 |
| Tidwell, RR | 2 |
| Pohlig, G | 2 |
| N'tombe, PM | 1 |
| Deo, GK | 1 |
| Mutantu, PN | 1 |
| Kuikumbi, FM | 1 |
| Mintwo, AF | 1 |
| Munungi, AK | 1 |
| Dala, A | 1 |
| Macharia, S | 1 |
| Franco, JR | 1 |
| Dituvanga, ND | 1 |
| Oliveira, LF | 1 |
| Schubach, AO | 1 |
| Martins, MM | 1 |
| Passos, SL | 1 |
| Oliveira, RV | 1 |
| Marzochi, MC | 1 |
| Andrade, CA | 1 |
| Wormser, GP | 1 |
| Krupp, LB | 1 |
| Hanrahan, JP | 1 |
| Gavis, G | 1 |
| Spira, TJ | 1 |
| Cunningham-Rundles, S | 1 |
| Valencia, ME | 1 |
| Gil, A | 1 |
| Lavilla, P | 1 |
| Pintado, V | 1 |
| López Dupla, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Single, Double and Triple Dose Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis: a Pilot Study[NCT02919605] | Phase 2 | 159 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Phase II A Trial of DB289 for the Treatment of Stage I African Trypanosomiasis[NCT00802594] | Phase 2 | 30 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Phase II b Trial of DB289 for the Treatment of Stage I African Trypanosomiasis[NCT00803933] | Phase 2 | 111 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pentamidine and Adverse Drug Event
| Article | Year |
|---|---|
Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.
Topics: Amphotericin B; Antimony; Antiprotozoal Agents; Drug-Related Side Effects and Adverse Reactions; Hum | 2011 |
[Drug surveillance for adverse reactions in patients with human immunodeficiency virus infection].
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Antitubercular Agents; Drug-Related Side Effects | 1990 |
3 trials available for pentamidine and Adverse Drug Event
7 other studies available for pentamidine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Evaluation of pentamidine tolerability and efficacy between
Topics: Antifungal Agents; Cytochrome P-450 CYP2C19; Drug-Related Side Effects and Adverse Reactions; Humans | 2023 |
Aerodigestive adverse effects during intravenous pentamidine infusion for Pneumocystis jirovecii pneumonia prophylaxis.
Topics: Adolescent; Adult; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, | 2021 |
Consecutive hypoglycemia attacks induced by co-trimoxazole followed by pentamidine in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Aged; Anti-Infective Agents; Atovaquone; Drug-Related Side Effec | 2019 |
Safe and Effective Prophylaxis with Bimonthly Intravenous Pentamidine in the Pediatric Hematopoietic Stem Cell Transplant Population.
Topics: Administration, Intravenous; Antifungal Agents; Chemoprevention; Child; Child, Preschool; Drug-Relat | 2016 |
Acquired immunodeficiency syndrome in male prisoners. New insights into an emerging syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Candida albicans; Drug-Related Side Effects and Adverse R | 1983 |